Menopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Diabetes

Exclusion Criteria

• •DPP4-inhibitor, SLGT2-inhibitor or sulfonylurea use within 8 weeks prior to study enrolment
• •GLP-1RA use within 6 months prior to study enrolment
• •Insulin therapy within 8 weeks prior to study enrolment
• •History of bariatric surgery
• •More than 2% change in body weight within three months prior to study enrolment (based on documented or reported weights)
• •Contraindications for the use of the study medication as per prescription labelling: Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2
• •Known or suspected cancer of breast or other sexual organ, abnormal genital bleeding of unknown cause, hepatic neoplasia
• •Arterial or venous thromboembolic events, porphyria
• •Known allergy or hypersensitivity to Wegovy®, Estradot® or Utrogestan® (pharmaceutical agents or any of the excipients)
• •Systemic hormone therapy or hormonal contraceptives (e.g. estrogens, progestogens, androgens) during the study and within 12 months prior to participation
• •Herbal remedies and complimentary medicines for menopausal symptoms during the study
• •Physical or psychological condition or any medical intervention (including medication not specified above) likely to interfere with the normal conduct of the study and interpretation of the study results as judged by the investigator
• •Participation in another clinical trial that interferes with the interpretation of the study results
• •Inability to read German
• •Unwillingness to follow the study procedures